Mesoblast Limited (ASX:MSB)

Market Cap	2.24B
Revenue (ttm)	9.16M
Net Income (ttm)	-167.00M
Shares Out	1.28B
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,381,204
Average Volume	5,591,241
Open	1.780
Previous Close	1.770
Day's Range	1.725 - 1.800
52-Week Range	0.880 - 3.370
Beta	1.42
RSI	52.69
Earnings Date	May 23, 2025

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.

Financial numbers in USD